We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

HNI:NYSEHNI Corporation Analysis

Data as of 2026-06-07 - not real-time

$31.14

Latest Price

7/10Risk

Risk Level: Medium

Executive Summary

HNI’s share price is trading below its 20‑day and 50‑day moving averages, confirming a bearish technical backdrop, while the MACD histogram has turned positive and the RSI sits in the mid‑range, hinting at limited upside momentum. Revenue surged 125% YoY in Q1, outpacing Wall Street’s expectations and delivering non‑GAAP earnings ahead of consensus, yet the company’s margins remain razor‑thin and free cash flow is negative. The dividend has been increased, offering a 4.5% yield, but the payout ratio exceeds 500%, raising sustainability concerns. Valuation metrics are starkly mismatched: the market price is more than three times the DCF‑derived fair value and the trailing P/E is sky‑high, while forward P/E appears modest, underscoring significant overvaluation. High 30‑day volatility and a recent max drawdown of over 40% amplify downside risk, especially in a consumer‑cyclical sector that is sensitive to economic headwinds.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 8/10

Key Factors

  • Price below key moving averages and bearish trend direction
  • Technical MACD signal turning bullish but insufficient to offset valuation gap
  • Elevated volatility and recent sharp drawdown

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • Strong revenue growth and earnings beat providing temporary support
  • Unsustainable dividend payout and negative free cash flow
  • Continued overvaluation relative to intrinsic value

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • Fundamentals indicate low profitability (near‑zero ROE) and high debt load
  • DCF fair value suggests a sizable downside potential
  • Consumer‑cyclical exposure could worsen in a prolonged economic slowdown

Key Metrics & Analysis

Financial Health

Revenue Growth124.70%
Profit Margin0.04%
P/E Ratio115.3
ROE0.12%
ROA4.34%
Debt/Equity97.41
P/B Ratio1.3
Op. Cash Flow$91.9M
Free Cash Flow$-5450000

Technical Analysis

TrendBearish
RSI43.6
Support$28.93
Resistance$34.94
MA 20$31.04
MA 50$33.71
MA 200$41.35
MACDBullish
VolumeDecreasing
Fear & Greed Index83.02

Valuation

Fair Value$9.37
Target Price$69.00
Upside/Downside121.58%
GradeOvervalued
TypeGrowth
Dividend Yield4.50%

Risk Assessment

Beta0.86
Volatility45.66%
Sector RiskHigh
Reg. RiskLow
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.